natgillin/translations-raw huggingface dataset:
6; an antibody comprising: a light chain comprising, according to IMGT, the CDR-L1 of the sequence SEQ ID No. 
41, te – teški lanac lanac koji prema IMGT sadrži CDR-H1 sekvencije SEQ ID No.
The pharmaceutical dosage formulation of claim 1, wherein the pharmaceutically acceptable carrier comprises a diluent, a binder, an adhesive, a disintegrant, a lubricant, an antiadherent, a gildant, or a combination thereof. 
Farmaceutska dozna formulacija prema bilo kojem od patentnih zahtjeva od 1 do 4, naznačena time što farmaceutski prihvatljiv nosač sadrži diluent, vezivo, adheziv, dezintegrator, lubrikant, antiadheziv, glidant, ili njihovu kombinaciju.
a first nucleotide sequence encoding a single-molecule DNA-targeting RNA comprising: 
prvi nukleotidni slijed, koji kodira RNA koja cilja na DNA, koja sadrži:
A composition suitable for control of diseases caused by phytopathogens comprising (A) a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) at least one compound selected from compounds known for their fungicidal activity; and a method of controlling diseases on useful plants, especially rust diseases on soybean plants. 
Pripravak koji je pogodan za nadzor bolesti uzrokovanih fitopatogenim organizmima uključujući (A) spoj formule Inaznačen time da je R1 difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj klorotalonil.
The preserving reagent in some embodiments comprises a buffer which is selected from the group consisting of BIS-TRIS, BIS-TRIS Propane, HEPES, HEPES Sodium Salt, MES, MES Sodium salt, MOPS, MOPS Sodium Salt, Sodium salt or Sodium Phosphate Buffer (monobasic, tribasic PO4). 
Reagens prema zahtjevu 1, naznačen time da pufer je odabran iz skupine koja sadrži monobazični kalijev fosfat i trobazični kalijev fosfat, BIS-TRIS, BIS-TRIS propan, HEPES, HEPES natrijevu sol, MES, MES natrijevu sol, MOPS, MOPS natrijevu sol, natrijevu sol, i natrijev fosfatni pufer.
An LED module of claim 32, wherein said temperature sensing device is a thermistor. 
LED modul iz patentnog zahtjeva 32, naznačen time, da je navedena naprava za detekciju temperature termistor.
The rim block cage according to one of the preceding claims, characterized in that the inlet openings (5a, 5b, 5c, 5d) are formed in a slit-like manner. 
WC košarica prema jednom od prethodnih zahtjeva, naznačena time da su ulazni otvori (4a, 4b, 4c, 4d) oblikovani na način kao s prorezom.
System according to claim 4, comprising, for one or each unit, an electronic circuit adapted to drive the winding thereof and adjust the angular position around the propulsive element. 
Sustav prema patentnom zahtjevu 6 ili 7 ili 8, koji za jednu ili svaku jedinicu sadrži strujni krug (Ca, Cb) prilagođen da pokreće njihov namotaj i prilagođava kutni položaj oko propulzivnog elementa.
the serine at position 3 of the BC loop (SEQ ID NO: 34) is substituted with an amino acid selected from the group consisting of A, C, D, F, H, I, K, L, N, Q, R, T, V, W, and Y; 
serin na položaju 3 u petlji BC (SEQ ID NO: 34) je zamijenjen aminokiselinom koju se bira iz skupine koju čine A, C, D, F, H, I, K, L, N, Q, R, T, V, W te Y;
Use of the compound of formula I-2 as defined in claim 1 in a process for manufacturing the compound of formula I-3 or a salt thereof. 
Uporaba spoja formule I2 kako je definirano u zahtjevu 1, naznačena time, da služi u postupku proizvodnje spoja sljedeće formule I3:
is of formula: where X is H or X is a protective group of the OH function, and the broken bond is the bond to the cyclopentyl core. 
aoox gdje X je H, ili je X zaštitna skupina za funkcionalnu skupinu OH, a prekinuta veza > je veza na ciklopentilnu jezgru.
A compound according to claim 1, wherein G is hydrogen, an alkali metal or alkaline earth metal. 
G je vodik, alkalijski metal ili alkalijski zemni metal.
Serotonin, like norepinephrine, is known to be an important chemical messenger participating in the transmission of nerve impulses in the brain. 
Poznato je da serotonin, slično norepinefrinu, predstavlja važan kemijski prenositelj poruka, koji sudjeluje u transmisiji živčanih impulsa u mozgu.
a protein comprising an amino acid sequence having homology of at least 50% with the amino acid sequence of SEQ ID No 2 and having a fructosyl-transferase activity. 
(C) protein koji ima aminokiselinski slijed homologan najmanje 50% aminokiselinskom slijedu u SEQ ID NO:21 ima aktivnost fruktozil-transferaze.
the anti-KIR antibody and anti-PD-1 antibody are formulated for separate administration; or 
(b) anti-KIR antitijelo i anti-PD-1 antitijelo su formulirani za odvojenu administraciju; ili
film coating the tablets from step (6). 
oblaganja filmom tablete iz koraka (6).
The integrated circuit according to claim 9 wherein the variable gap is a largest gap which is an integer multiple of the RBG size and which is available based on the applicable system bandwidth. An integrated circuit to control a process, the process comprising, 
Integrirani krug sukladno jednom od zahtjeva 1 do 14, naznačen time da je razmak najveći od razmaka koji su cjelobrojni višekratnici broja uzastopnih PRB-ova koji tvore RBG 1 koji su dostupni ovisno o propusnosti sustava.
The composition of claim 31 wherein the second compound having anti-HCV activity is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5′-monophospate dehydrogenase inhibitor, amantadine, and rimantadine. 
Formulacija u skladu sa patentnim zahtjevom 7 gdje je najmanje jedan od dodatnih spojeva odabran od interleukina 2, interleukina 6, interleukina 12, spoj koji poboljšava razvoj odgovora tipa 1 pomoćnih T stanica, interferirajuće RNK, antisens RNK, imikvimoda, ribavirina, inhibitor inozin 5'-monofosfat dehidrogenaze, amantadina, i rimantadina.
the polypeptide is fused to at least one heterologous polypeptide, wherein the heterologous polypeptide is a human Fc domain; or 
polipeptid je spojen s najmanje jednim heterolognim polipeptidom, pri čemu je heterologni polipeptid ljudska Fc domena; ili
Preparation of the compounds of the invention 
Broj objave europskog patenta:
affixing a second one of said plurality of synthetic thatch members to an adjacently positioned portion of said roofing structure, such that said first and second ones of said plurality of synthetic thatch members are both positioned substantially along the same horizontal plane, and such that at least a portion of said fused portion of said second one of said plurality of synthetic thatch members at least partially overlaps at least a portion of said fused portion of said first one of said plurality of synthetic thatch members. 
učvršćivanje drugog navedenog mnoštva sintetskih slamnatih elemenata na susjedno smješteni dio navedene krovne konstrukcije, tako da su navedeni prvo i drugo od navedenog mnoštva sintetskih slamnatih elemenata oba smještena uglavnom uzduž iste vodoravne ravnine, te tako da barem dio navedenog spojenog dijela navedenog drugog navedenog mnoštva sintetskih slamnatih elemenata barem djelomično preklapa barem dijelove navedenog spojenog dijela navedenog prvog navedenog mnoštva sintetskih slamnatih elemenata.
R21A and R24A are independently selected from the group consisting of hydrogen, an optionally substituted C1-24 alkyl, an optionally substituted aryl, an optionally substituted -O-C1-24 alkyl and an optionally substituted -O-aryl; 
R"* i R* su neovisno odabrani iz skupine koja sadrži vodik, po izboru supstituiran C;.», alkil, po izboru supstituiran aril, po izboru supstituiran -O-C,.4 alkil i po izboru supstituiran -O-aril;
The pharmaceutical composition according to one of the previous claims characterized in that the amount of the glucopyranosyl-substituted benzene derivative is in a range from 5 to 50 mg per day for a human being. 
Farmaceutski sastav prema jednom od prethodnih zahtjeva, naznačen time, da sadrži količinu od 5 do 50 mg derivata benzena supstituiranog glukopiranozilom.
government regulations, environmental concerns, and material costs it is desired to recycle the bottle when it is emptied. 
zakonskih propisa, koji se odnose na zaštitu okoline, i troškova materijala, poželjno je da se bocu reciklira kad se isprazni.
A4b is absent or represents C1-C3alkylene, C2-C3alkenylene; or a radical selected from the group consisting of —CH2NH—, —CH2O—, and —CH2S—, said radical being linked to G via the nitrogen, oxygen or sulfur atom; or when L1 is N(R5)E and E is an amino protecting group said protecting group is removed and the deprotected intermediate is reacted with a compound of formula III above. 
A4b je odsutan ili predstavlja C,;-C3alkilen, C2-Czalkenilen ili skupinu koju se bira između -CH,NH-, 1 - CH>S-, gdje je navedena skupina vezana na G preko atoma dušika, kisika ili sumpora; ili kada je LI N(RSJE, a E je zaštitna skupina za amino, navedenu zaštitna skupina se uklanja, a međuprodukt s kojeg je skinuta zaštita reagira sa spojem formule III kao što je definirano gore.
Inhaler device according to claim 1, wherein each of the two capsule seat parts (14') is suitable for blocking the capsule (2) by interference with walls of the operculum. 
Aparat za imnhalaciju prema patentnom zahtjevu 1, pri čemu je svaki od dva sjedišna dijela (14) kapsule pogodan za blokiranje kapsule (2) interferencijom sa zidovima poklopca.
filled PP (co)polymcr in an amount in the range of 15% to 40%, preferably 30% to 35%; 
PP (ko)polimer s punilom u količini u području od 15 do 40 tež.%, prvenstveno 30 do 35 tež.%;
incubating the terpene component with the glucan particle or hollow cell wall particle at atmospheric pressure at a temperature of 20 to 37°C; and 
Metoda temeljem bilo kojeg od zahtjeva 44 do 53 gdje u koraku c) reakcija se provodi pri atmosferskom tlaku na temperaturi od 20 do 37°C.
The pharmaceutical composition or single unit dosage form for use of claim 2 or 3, wherein method involves administering the crystalline 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione by oral, parenteral or sublingual route of administration. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 38 do 43, naznačena time što se kristalni 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion pripravlja za oralnu, parenteralnu, nazalnu, topikalnu ili sublingvalnu primijenu.
A process for preparing a compound according to formula (1), or tautomer, or salt thereof, 
69. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (1) ili
A compound according to claim 3 wherein RA is a monocyclic C5-C7 cycloalkyl group. 
Spoj u skladu s patentnim zahtjevom 3, naznačen time što R* je monociklička Cs-C; cikloalkilna skupina.
The system is preferably programmed to require that the button be held down for about three seconds, to insure that the button is being pressed intentionally. 
Sustav je po mogućnosti programiran tako da zahtijeva da gumb bude pritisnut otprilike tri sekunde, kako bi se osiguralo da je gumb bio namjerno pritisnut.
Titanium tertraisopropyl (1.03 g, 0.0036 mol) was added to a solution of omeprazole in dry isopropanol (250 ml) and the mixture was stirred under N2 at room temperature for 4h. 
Titan tetraizopropilat (1,03, 0,0036 mola) je dodan u otopinu omeprazola u suhom izopropanolu (250 ml) i smjesa je miješana pod N> na sobnoj temperaturi 4 h.
reacting Compound 9 with an acid to produce Compound 10. 
reakciji Spoja 9 s kiselinom kako bi se dobilo Spoj 10:
The compound of aspect 43, wherein the human papilloma virus is selected from the group consisting human papilloma virus type 11, type 16 and type 18. 
(b) ljudski papilomavirus je odabran iz skupine koja se sastoji od ljudskog papilomavirusa tipa 11, tipa 16 i tipa 15.
A combined preparation according to claim 11, wherein the steroid is prednisolone acetate or fluorometholone and the non-steroidal antinflammatory drug is flurbiprofen. 
Kombinirani pripravak prema patentnom zahtjevu 11, naznačen time da steroid jest prednisolon-acetat ili fluormetolon te da nesteroidno antiupalno sredstvo jest flurbiprofen.
producing an active ingredient trituration wherein the active ingredient is pramipexole or a pharmaceutically acceptable salt thereof by preblending it with a portion of water swelling polymers and/or excipient(s) in a mixer, wherein pramipexole or the pharmaceutically acceptable salt thereof is milled, preferably peg-milled, prior to use; 
(1) pripravu triturata aktivnog sastojka pri čemu je aktivni sastojak pramipeksol ili njegova farmaceutski više pomoćnog sredstva u mjošalici, pri čemu su pramipeksol ili njegova farmaceutski prihvatljiva sol mljeveni, povoljno je mljeveni u klinastom mlinu prije uporabe;
The compound of paragraph 34 wherein R5 is selected from the group consisting of H, -C(=O)N(R9)2 and -CN. 
Spoj prema zahtjevu 6, naznačen time da R? je odabran iz skupine koja sadrži H, -C(=0)N(R*),, te -CN.
A compound which is represented by the following structure: or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease or disorder which is selected from genitourinary cancer, glioblastoma, small bowel cancer, and breast cancer. 
HOMO Prah x x ili njegova farmaceutski prihvatljiva sol, pri čemu se on upotrebljava u liječenju bolesti ili poremećaja koja/i je odabran/a od sljedećih: genitalno-urinarni rak, glioblastom, rak tankog crijeva i rak dojke.
r is 0, or 1 and when r is 0 then a direct bond is intended; 
r je 0, ili 1 i kada r je 0 tada je namjeravana direktna veza;
A macromolecule for use as claimed in Claim 1, wherein the macromolecule is administered in an amount of from 40 mg to 60 mg per day. 
Makromolekula za uporabu u skladu s patentnim zahtjevom 1, pri čemu je makromolekula primijenjena u količini od 40 mg do 60 mg na dan.
Step 3: The compound (VI) is then transformed into compound (VII) by eliminating HCl, preferably in an alkaline medium (dehydrohalogenation). 
Korak 3: Spoj (VI) se nakon toga pretvori u spoj (VID) eliminacijom HCl, poželjno je u alkalnom mediju (dehidrohalogeniranje).
an operation device (90; 42; 54; 40; 217; 218; 452) configured to operate the stretching device when implanted, to stretch the stomach wall portion such that temporary satiety is created, 
usadljivi uređaj za rukovanje (90; 42; 54; 40; 217; 218; 452), namijenjen rukovanju uređajem za rastezanje kada je usađen, kako bi rastegnulo dio stijenke želuca, tako da se stvori osjećaj sitosti, naznačen time što je upravljivi uređaj za rastezanje prilagođen za stavljanje s vanjske strane stijenke želuca.
The aqueous layer was extracted with ethyl acetate, washed with water, concentrated under reduced pressure followed by product distillation to give 19.6 g of 6-fluoro-3,4-dihydro-2-oxiranyl-2H-1-benzopyran (VII) in the form of a mixture of A and B as an oil. 
Vodeni sloj je ekstrahiran s etil acetatom, ispran s vodom, koncentriran pod sniženim tlakom nakon čega je slijedila destilacija produkta da bi se dobilo 19,6 g 6-fluoro-3,4-dihidro-2-oksiranil-2H- benzopirana (VII) u obliku mješavine A i B kao ulja.
Use of a drug delivery device comprising a fibrillar collagen matrix; and at least one drug substance, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least one day after administration for the manufacture of a medicament for providing local analgesia, local anesthesia or nerve blockade in the human or animal in need thereof, the analgesia, anesthesia or nerve blockade comprising administering the medicament at the site in a human or animal in need thereof wherein the drug delivery device comprises a plurality of collagen sponges, wherein the number and size of implanted sponges provides a drug dose within a daily dose limit of 400mg of bupivacaine hydrochloride. 
Uporaba naprave za dopremu lijeka koja sadrži matricu od fibrilarnog kolagena; i barem jednu ljekovitu tvar, najmanje jedna ljekovita tvar je sadržajno homogeno raspršena u matrici kolagena, i najmanje jedna ljekovita tvar je prisutna u količini dovoljnoj za omogućavanje djelovanja lokalne analgezije, lokalne anestezije ili blokade živca u trajanju od najmanje jednog dana nakon primjene za proizvodnju lijeka za omogućavanje lokalne analgezije, lokalne anestezije ili blokade živca kod potrebitog čovjeka ili životinje, analgezija, anestezija ili blokada živca obuhvaća davanje lijeka na određeno mjesto kod potrebitog čovjeka ili životinje pri čemu naprava za primjenu lijeka sadrži množinu spužava kolagena, svaka spužva kolagena ima 3.6 do 8 mg/cm3 kolagena tipa I i 2.0 do 6.0 mg/cm3 bupivakain hidroklorida.
The liquefied gas treatment system according to claim 1, wherein a gas component separated in the gas-liquid separator (23) is mixed with the first stream of boil-off gas discharged from the storage tank and is supplied to the compressor (13,13a,13b) together with the first stream. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 2, naznačen time što se plinovitu komponentu u trećoj struji, dekomprimiranoj u plinsko-tekuće miješano stanje, spaja s prvom strujom otparenog plina, ispuštenog iz spremnika za teret (11).
They may also reduce oxidation reactions in skin tissueAnti-oxidants prevent oxidative deterioration which may lead to the generation of rancidity and nonenyzymatic browning reaction products. 
Oni mogu također smanjiti oksidacijske reakcije u kožnom tkivu. Antioksidansi sprečavaju oksidativno propadanje koje može dovesti do razvoja užeglosti i produkata reakcije neenzimatskog tamnjenja.
A combination according to claim 1 or 2, wherein the corticosteroid is selected from the group comprising dexamethasone, budesonide, beclomethasone, triamcinolone, mometasone, ciclesonide, fluticasone, flunisolide, dexamethasone sodium phosphate and esters thereof as well as 6a,9a-difluoro-17a-[(2-furanylcarbonyl)oxy]-11B-hydroxy-16a-methyl-3-oxoandrosta-1,4-diene-17B-carbothioic acid (S)-fluoromethyl ester. 
Kombinacija u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da je kortikosteroid odabran iz skupine koja se sastoji od deksametazona, budesonida, beklometazona, triamcinolona, mometazona, ciklesonida, flutikasona, flunisolida, deksametazon natrij fosfata i njihovih estera kao i 649f-difluoro-17a-[2-furanilkarbonil)oksi]-11f- hidroksi-1 6a-metil-3-oksoandrosta-1,4-dien-175-(S)-fluorometil ester karbotio kiseline.
separating the resin from the plasma-derived protein composition, wherein the plasma-derived target protein does not bind to the chromatographic resin in sub-step (i). 
odvajanje smole iz sastava proteina koji je izveden iz plazme, pri čemu ciljani protein koji je izveden iz plazme, nije vezan za kromatografsku smolu u podfazi (i).
A thermally insulating stretchable down feathersheet (10) as claimed in claim 1 wherein said binder (15) is further constituted by heat fusible dry glue particles mixed with said down feathers (14) in said predetermined proportions and being stretchable after being subjected to heat treatment. 
Toplinski izolirajući rastezljivi sloj paperja (10) u skladu s patentnim zahtjevom 1, naznačen time što navedeno vezivo (15) dodatno sadrži toplinski spojive čestice suhog ljepila pomiješane s navedenim paperjem (14) u navedenim zadanim udjelima i može se rastezati nakon podvrgavanja toplinskoj obradi.
Then, the customers buy the "fancy plywood" and cut out the part of the panel that they need. 
Nakon toga kupci kupuju "ukrašenu šperploču" i izrezuju dio ploče koji trebaju.
In a particular preferred aspect, said cancer is a cancer chosen from prostate cancer, osteosarcomas, lung cancer, breast cancer, endometrial cancer, glioblastoma or colon cancer. 
Antitijelo ili pripravak za upotrebu prema patentnom zahtjevu 11, naznačeno time da rečemi karcinom jest karcinom odabran od karcimoma prostate, osteosarkoma, karcinoma pluća, karcinoma dojke, karcinoma endometrija, glioblastoma ili karcinoma debelog crijeva.
Nicotine-containing granulate according to one of claims 1 to 5, characterized in that the excipient is selected from the group consisting of monosaccharides, disaccharides, hydrated or non-hydrated oligosaccharides, monosaccharide alcohols, disaccharide alcohols, starch, starch derivatives, cellulose, cellulose derivatives, inulin, sugar alcohols, calcium carbonate, calcium hydrogenphosphate, maltodextrins, polysaccharides, and combinations thereof. 
Postupak dobivanja granulata koji sadrži nikotin u skladu s bilo kojim od patentnih zahtjeva 4 do 6, naznačen time što se pomoćnu tvar upotrijebljenu u koraku (a) bira iz skupine koju čine monosaharidi, disaharidi, hidratirani ili nehidratirani oligosaharidi, monosaharidni alkoholi, disaharidni alkoholi, škrob, škrobni derivati, celuloza, inulin, šećerni alkoholi, kalcijev karbonat, kalcijev hidrogenfosfat, maltodekstrini, polisaharidi, te njihove kombinacije.
Additionally WO 02/055720 (The University Court of the University of Aberdeen) discusses the use of reduced forms of diaminophenothiazines specifically for the treatment of a variety of protein aggregating diseases, although the disclosure is primarily concerned with tauopathies. 
Uporaba diaminofenotiazinskog spoja, naznačena time, da je za proizvodnju lijeka za liječenje blagog kognitivnog poremećaja (BKP) kod pacijenta koji od njega boluje, gdje se navedeni spoj bira od spojeva slijedećih formula:
On completion of the reaction, the reaction mixture was concentrated under vacuum to a solid, then taken up in methanol/dimethyl sulfoxide/water and purified by preparative HPLC, and the product-containing fractions again lyophilized. 
Po završetku reakcije, reakcijska smjesa koncentrirana je pod vakuumom do krutog, potom prenešena u metanol/dimetil sulfoksid/voda i pročišćena pomoću preparativne HPLC, a produkt koji sadrži frakcije ponovo je liofilizira.
In most cases, this is an important aspect of the valve as, for instance, in the case of medical inhalers, it is important that the patient receives no less or no more than the appropriate metered dose. 
U većini slučajeva to je važno svojstvo ventila, kao, na primjer, u slučaju medicinskih inhalatora, gdje je važno da pacijent primi ni manje, ni više od odmjerene doze. kad se dosegno otvoren položaj.
3 shows the enclosing unit according to the present invention without the main frame 26 in order to have a better view of the static and moveable parts housed inside and mounted to the main frame 26 . FIG. 
Slika 3 prikazuje jedinicu za zatvaranje, koja je u skladu s predmetnim izumom, bez glavnog okvira 26 kako bi se imao bolji pogled na statičke 1 pokretne dijelove koji su smješteni unutar glavnog okvira 26 i montirani su na njega.
said first pawl rides over one of said plurality of teeth during said return stroke. A counter according to any one of claims 1 to 7, wherein said first and second pawls are integral with said first ring member, and said plurality of teeth are disposed on a teeth-bearing member arranged to be reciprocally moveable within the bore of said first ring member, and wherein said pawl-and-teeth mechanism is configured such that reciprocal movement of the teeth-bearing member within the bore of the first ring member causes rotational movement of the first ring member. 
Brojač kao što je navedeno u bilo kojem od zahtjeva 1 do 3, naznačeno time da su navedeni prvi i drugi zapinjači (402a, 402b) integralni s prvim prstenastim elementom (201), i navedeni pluralitet zuba (210) je postavljen na element za držanje zubi (206) smješten da bude recipročno pomičan unutar provrta navedenog prvog prstenastog elementa, i naznačeno time da je navedeni mehanizam zapinjača i zubi konfiguriran na način da recipročno kretanje elementa za držanje zubi unutar provrta prvog prstenastog elementa uzrokuje rotacijsko kretanje prvog prstenastog elementa.
More particularly, in the method as defined above, a saponification step is carried out before the extraction of the cholesterol. 
Postupak u skladu s patentnim zahtjevom 9 ili 10, naznačen time što se prije ekstrakcije kolesterola provodi korak saponificiranja.